GLP-1 receptor agonists are not associated with an increased risk for suicidality compared with DPP-4 inhibitors or SGLT-2 inhibitors.

Emapalumab-Izsg is under the FDA’s Priority Review for hemophagocytic lymphohistiocytosis/macrophage activation syndrome in Still disease.

In a US study, researchers found that 35% of adults with IBD screened positive for spondyloarthritis, despite having no known SpA diagnosis.

Filgotinib maintained a favorable safety and efficacy profile for up to 8 years among patients with RA who participated in the DARWIN 3 LTE.

Chronic diseases misdiagnosed as psychosomatic can lead to long-term damage to patients' physical and mental well-being.

A presidential advisory has been published by the AHA regarding US government funding for the National Institutes of Health.

Higher adherence to the Mediterranean diet is associated with a modest reduction in the risk for obesity-related cancers.

A recent study finds that nonmalignant gynecological diseases are associated with cardiovascular and/or cerebrovascular disease.

For patients with moderate-to-severe plaque psoriasis, ixekizumab is effective and safe, with induction therapy enhancing initial response.

Patients with RA who have used b/tsDMARDs demonstrated similar risks for multiple myeloma when compared with those taking only csDMARDs.

Romosozumab vs bisphosphonate use was not linked to increased CVD risks among patients with osteoporosis, challenging past concerns over its cardiovascular safety.

Interruptive clinical decision support increased face-to-face suicide screening rates, with no 30-day suicide events following study encounters.